Search results for " vaccini"

showing 10 items of 10 documents

Efficient Delivery of Human Cytomegalovirus T Cell Antigens by Attenuated Sendai Virus Vectors.

2018

ABSTRACT Human cytomegalovirus (HCMV) represents a major cause of clinical complications during pregnancy as well as immunosuppression, and the licensing of a protective HCMV vaccine remains an unmet global need. Here, we designed and validated novel Sendai virus (SeV) vectors delivering the T cell immunogens IE-1 and pp65. To enhance vector safety, we used a replication-deficient strain (rdSeV) that infects target cells in a nonproductive manner while retaining viral gene expression. In this study, we explored the impact that transduction with rdSeV has on human dendritic cells (DCs) by comparing it to the parental, replication-competent Sendai virus strain (rcSeV) as well as the poxvirus …

0301 basic medicineHuman cytomegalovirusModified vaccinia AnkaraT cellmedicine.medical_treatmentvirusesImmunologyGenetic VectorsAlpha interferonCytomegalovirusMice TransgenicMicrobiologySendai virusViral Matrix Proteins03 medical and health sciencesCytomegalovirus VaccinesMiceTransduction GeneticVirologyCricetinaeChlorocebus aethiopsVaccines and Antiviral AgentsmedicineCytotoxic T cellAnimalsHumansAntigens ViralVero Cellsbiologyvirus diseasesImmunotherapymedicine.diseasebiology.organism_classificationPhosphoproteinsVirologySendai virus030104 developmental biologymedicine.anatomical_structureViral replicationInsect ScienceJournal of virology
researchProduct

Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a rando…

2019

PMC6682346; Pexastimogene devacirepvec (Pexa-Vec) is a vaccinia virus-based oncolytic immunotherapy designed to preferentially replicate in and destroy tumor cells while stimulating anti-tumor immunity by expressing GM-CSF. An earlier randomized Phase IIa trial in predominantly sorafenib-naive hepatocellular carcinoma (HCC) demonstrated an overall survival (OS) benefit. This randomized, open-label Phase IIb trial investigated whether Pexa-Vec plus Best Supportive Care (BSC) improved OS over BSC alone in HCC patients who failed sorafenib therapy (TRAVERSE). 129 patients were randomly assigned 2:1 to Pexa-Vec plus BSC vs. BSC alone. Pexa-Vec was given as a single intravenous (IV) infusion fol…

0301 basic medicineSorafenibOncologylcsh:Immunologic diseases. Allergymedicine.medical_specialtyHepatocellular carcinomamedicine.medical_treatmentImmunologyPexastimogene-devacirepvecAucunSciences du Vivant [q-bio]/Médecine humaine et pathologielcsh:RC254-28203 medical and health scienceschemistry.chemical_compound0302 clinical medicineAntigenInternal medicinemedicineClinical endpointImmunology and AllergyHepatocellular carcinoma; oncolytic immunotherapy; oncolytic vaccinia; Pexa-Vec; sorafeniboncolytic vacciniaOriginal Researchbusiness.industryImmunotherapymedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens3. Good healthOncolytic virus030104 developmental biologyOncologychemistry030220 oncology & carcinogenesisHepatocellular carcinomaPexa-Veconcolytic immunotherapysorafenibVacciniabusinesslcsh:RC581-607[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologymedicine.drug
researchProduct

Vaccinium macrocarpon (Cranberry)-Based Dietary Supplements: Variation in Mass Uniformity, Proanthocyanidin Dosage and Anthocyanin Profile Demonstrat…

2020

Vaccinium macrocarpon (syn. American Cranberry) is employed in dietary supplements (DS) with the aim to improve urinary tract well-being. This property is linked to the antiadhesion-activity of proanthocyanidins (PACs) against uropathogenic-bacteria. However, the current European legislation has been criticized for being weak and ineffective. Indeed, recent scientific works report mislabeled, contaminated, and adulterated supplements containing dangerous or unknown compounds, or sold at toxic doses. In this work, we analysed 24 DS that claim to contain cranberry, and to have a specific dosage of PACs. Our tests included the control of the good manufacturing practice according to the Europea…

<i>Vaccinium macrocarpon</i>Anthocyanin0301 basic medicineSettore CHIM/10 - Chimica Degli Alimentilcsh:TX341-641Articlechemical fingerprintinglaw.inventionAnthocyaninsdietary supplements03 medical and health scienceschemistry.chemical_compoundBL-DMAC0404 agricultural biotechnologyfoodlawSettore BIO/10 - BiochimicaAmerican cranberry; Anthocyanins; BL-DMAC; Chemical fingerprinting; Dietary supplements; HPLC-UV/Vis; Orbitrap; Proanthocyanidins; Vaccinium macrocarponEuropean marketVaccinium macrocarponMedicineProanthocyanidinsFood scienceAmerican cranberry030109 nutrition & dieteticsNutrition and Dieteticsbusiness.industryHPLC-UV/Vis04 agricultural and veterinary sciencesOrbitrap040401 food scienceAmerican cranberryfood.foodVaccinium macrocarponProanthocyanidinchemistrydietary supplementAnthocyaninProanthocyanidinPharmacopoeiaHPLC-UV/Vibusinesslcsh:Nutrition. Foods and food supplyChemical fingerprintingFood ScienceNutrients
researchProduct

Responsabilità del produttore per danno da vaccino e onere della prova

2018

L'articolo esamina la responsabilità del produttore per i danni causati da un vaccino difettoso, in relazione alla possibilità di applicare la direttiva 85/374/CEE. Ci si sofferma segnatamente sulla questione correlata alla prova del nesso causale tra la somministrazione del vaccino e la comparsa dei danni, quando essa non è suffragata da fondamento scientifico, ponendo attenzione alle motivazioni della sentenza della Corte di giustizia UE del 21 giugno 2017 (C-621/15), favorevole a supplire l'assenza di prova mediante il ricorso a indizi seri, precisi e concordanti forniti dal danneggiato. Il punto di vista della Corte è esaminato, palesando i rischi di una eccessiva divaricazione tra la s…

Danno da vaccini difettosiSettore IUS/01 - Diritto PrivatoResponsabilità del produttoreIncertezza scientifica
researchProduct

Botāniskā dārza sekciju "Augu daudzveidības pētījumi ex situ" un "Augu selekcija un introdukcija" tēžu krājums (2020. gada 30. janvāris, LU Botāniska…

2020

Latvijas Universitātes 78. starptautiskā zinātniskā konference LU Botāniskajā dārzā notiek 2020. gada 30. janvārī. Krājumā ir 13 ziņojumu kopsavilkumi: pieci kopsavilkumi LU prioritārās tēmas "Ekoloģija un bioloģiskā daudzveidība" apakštēmas/sekcijas "Augu daudzveidības pētījumi ex situ" un astoņi kopsavilkumi sekcijas "Augu selekcija un introdukcija" ziņojumiem.

Rododendru selekcijas un izmēģinājumu audzētava “Babīte”bioloģiskā daudzveidībaBotanical gardendārzbēgļiEkoloģijaAugu nosaukumiBotanySibīrijas mēlziedes Ligularia sibiricaprojekts “Dārza pērles” EST LAT 70 - LU Botāniskais dārzsMagnoliju kolekcija - LU Botāniskais dārzs:NATURAL SCIENCES::Biology [Research Subject Categories]kukaiņu sugas rododendrosplant collectionsBrūkleņu Vaccinium vitis-idaea audzēšanaAugu selekcijakokaugu kolekcija - Nacionālais botāniskais dārzs
researchProduct

Questioni di legittimità costituzionale dell’art. 4 del d.l. n. 44 del 2021. Spunti di riflessione a margine dell’ordinanza n. 38/2022 del Consiglio …

2022

L'articolo affronta il tema dell'obbligo vaccinale con particolare riferimento al dibattitto giurisprudenziale dinanzi al giudice amministrativo

Settore IUS/08 - Diritto CostituzionaleObbligo vaccini costituzionalità
researchProduct

Vaccinazioni: stato dell’arte, falsi miti e prospettive. Il ruolo chiave della prevenzione.

2017

La pratica vaccinale in Italia è organizzativamente incardinata all’interno del Servizio Sanitario Nazionale (SSN) e nei Servizi Sanitari Regionali (SSR). I luoghi “classici” in cui viene effettuata la procedura/prestazione vaccinale sono i servizi di vaccinazione della Aziende Sanitarie Locali (ASL) o Provinciali (ASP) delle varie Regioni.

VaccinazioneprevenzioneVaccinazione; vaccini; prevenzionevacciniSettore MED/42 - Igiene Generale E Applicata
researchProduct

Zileņu (Vaccinium uliginosum L.), melleņu (Vaccinium myrtillus L.) un krūmelleņu (Vaccinium corymbosum) ķīmiskais sastāvs un bioloģiskā aktivitāte

2015

Zileņu Vaccinium uliginosum L. un melleņu Vaccinium myrtillus L. izplatība ir Eiropas ziemeļu augsto purvu un mitro mežu areālā, skuju koku un jaukto koku mežos, īpaši retainēs un izcirtumos, savukārt krūmellenes Vaccinium corymbosum tiek audzētas kā kultūraugi. Ķīmiskais sastāvs un bioloģiskā aktivitāte, kā arī dažādu vitamīnu un vielu saturs, ogās ir ļoti augsts. Zilās ogas potenciāli labvēlīgi iedarbojas uz cilvēku veselību gan kā profilakses līdzeklis, gan kā ārstniecības līdzeklis. Neskatoties uz zileņu labajām īpašībām, cilvēku vidū lielāku popularitāti ir ieguvušas mellenes un krūmmellenes, kura bieži tiek jauktas ar zileni, tāpēc Vaccinium uliginosum L. ir maz pētīta suga. Bakalaura…

ekstrakcijazilenes Vaccinium uliginosum L.Vides zinātnekrūmellenes Vaccinium corymbosumpolifenolimellenes Vaccinium myrtillus L.
researchProduct

Parasitoids (Hymenoptera) of leaf-spinning moths (Lepidoptera) feeding on Vaccinium uliginosum L. along an ecological gradient in central European pe…

2011

Parasitoids of leaf-spinning Lepidoptera associated with two isolated central European peat bogs were investigated. Five families of parasitoid Hymenoptera (Braconidae, lchneumonidae, Eulophidae, Pteromalidae and Encyrtidae) were recorded. Three categories were recognised: (1) primary parasitoids, (2) facultative hyperparasitoids and (3) obligatory hyperparasitoids. Ten species of Braconidae, five species and seven marked morphospecies among lchneumonidae, and three species of Chalcidoidea were identified. Despite of some niche-specific (but less host-specific) parasitoids, all these hymenopterans are likely to be generalists and none of them were confirmed to be habitat and/or host special…

geographyPeatgeography.geographical_feature_categorybiologyEcologyVaccinium uliginosumHymenoptera parasitoids Vaccinium uliginosum peat bogs leaf-spinning moths ecological gradient Ichneumonidae Community revisionWetlandHymenopteraICHNEUMONIDAEbiology.organism_classificationREVISIONCOMMUNITYLepidoptera genitaliaSettore AGR/11 - Entomologia Generale E ApplicataHabitatInsect ScienceBotanyEcological gradientArtikkelitBog
researchProduct

Meža melleņu antocianīnu ekstrakta bioloģisko efektu izpēte intervences pētījumā geriatrijas pacientiem

2020

Dažādos zinātniskos pētījumos antocianīni uzrāda augstus antioksidatīvos efektus, pretiekaisuma iedarbību, kā arī spēju samazināt kardiovaskulāro slimību risku. Cilvēka organismam novecojot pieaug oksidatīvais stress un tā radītie bojājumi sekmē arī iekaisuma procesu veidošanos, vienlaikus paaugstinot hronisko saslimšanu riskus geriatrijas vecuma cilvēkiem. Darba mērķis bija noskaidrot meža melleņu antocianīnu ekstraktu saturoša uztura bagātinātāja intervences ietekmi, apskatot ar novecošanos saistītu asins bioķīmisko marķieru izmaiņas geriatrijas pacientiem. Rezultāti liecina, ka pēc 4 nedēļu meža melleņu antocianīnu ekstrakta kapsulu lietošanas 2 reizes dienā (50 mg/kaps.) ir droša geriat…

geriatrijas pacientiantocianīniFarmācijaintervences pētījumsmeža mellenes Vaccinium myrtillus L.asins biomarķieri
researchProduct